Bone metastasis is a common phenomenon in patients with advanced prostate cancer. The molecular and cellular mechanisms involved in this process are not well understood. Past reviews on this subject primarily focused on prostate tumor growth in the bone marrow and the effects this growth has on bone homeostasis (ie osteoblastic and osteolytic). Cell chemotaxis and adhesion are also important for site-speci®c metastasis. In this review we have focused on chemotactic and cell adhesion molecules potentially involved in prostate cancer metastasis to bone. In addition, recently developed animal models for prostate cancer metastasis to bone are discussed. Prostate Cancer and Prostatic Diseases (2000) 3, 6±12.
Introduction
Prostate cancer bone metastasis is a major clinical problem and is commonly associated with intractable pain, pathological fracture and spinal cord compression. 1 Previous reviews of prostate cancer metastasis have focused predominately on tumor growth in the bone microenvironment and the effects that tumor growth has on bone homeostasis (ie osteoblastic and osteolytic). 2, 3 The growth rate of prostate cancer cells accelerates once they enter the bone environment, suggesting that factors are present in bone that stimulate tumor proliferation. Bone ®broblast-derived factor and transferrin are two of several molecules that have been shown to be mitogenic for prostate cancer cells. 4, 5 A recent article by Koeneman et al, hypothesized and demonstrated that prostate cancer cells propagate well in bone because they acquire osteomimetic properties. 6 Using the LNCaP animal model system, the authors demonstrated that the progression of prostate cancer mimics the maturation of osteoblast cells. 7 The inactivation of parathyroid hormone-related protein (PTH-rp) by prostate-speci®c antigen may promote the osteoblastic reaction seen in prostate cancer patients. Yoneda has proposed that the minor osteolytic reaction observed in bone lesions of prostate cancer patient is due to cross-talking between metastatic prostate cancer cells, osteoblasts and osteoclasts. 3 The activation of osteoclasts causes bone resorption and provides space, calcium, and bone-derived growth factors that are needed for the ensuing osteoblastic reaction. In addition, these growth factors can further stimulate prostate tumor proliferation. 3 The scenario is different in breast cancer because the predominate effect is osteolytic. Breast cancer cells produce PTH-rp, which is a potent activator of osteoclasts promoting bone destruction. Bone-derivedgrowth factors are then released, such as transforming growth factor-beta (TGF-b). TGF-b can further stimulate breast tumors to produce PTH rp, creating a vicious cycle in the bone proper. 3, 8 Cell chemotaxis, cell adhesion, and selective tumor growth at preferred sites are three important steps required for site-speci®c metastasis (Figure 1 ). 9 As outlined above, the data regarding tumor growth in bone has been reviewed extensively and therefore the focus of this article is to review the data on potential chemotactic and cell adhesion molecules responsible for bone metastasis. In addition, recent developments and advancements in animal models for bone metastasis will be discussed.
Chemoattractants
The dissemination of tumor cells to speci®c organs may be directed, in part, by chemoattractants. 10 Hujanen and Terranova investigated the ability of a variety of tumor cells to migrate to extract derived from organs primarily targeted for metastasis. 10 Using a Boyden chamber assay, it was demonstrated that B16-Br2 melanoma cells, which metastasize to the brain, migrated more to brain derived extract. Lung extract preferentially attracted lung metastasizing T241-PM2 ®brosarcoma cells. Murine M50 ± 76 reticulum cell sarcoma cells, which metastasize to liver and ovaries, selectively migrated more to liver extract, while bone and brain metastasizing MCF-7 breast adenocarcinoma cells migrate mostly to both bone and brain extracts. This data suggests that tissues contain speci®c chemotactic factors for tumor cells that preferentially metastasize to them.
Bone is constantly being remodeled and subsequently releases potential chemoattractive molecules for exposure to circulating tumor cells (Figure 1 ). 9, 11 It was hypothesized that osteoblast products, directly secreted or released from the bone matrix by osteoclasts resorbing activity, are potential chemoattractive agents for bone colonizing tumor cells. 12 This hypothesis was tested using an in vitro system of differentiating osteoblasts. The data demonstrated that osteoblast products found in conditioned media were able to attract breast and melanoma tumor cells. In addition, osteoblast-conditioned media stimulated production of matrix metalloproteinases in cancer cells. These activities were most pronounced with conditioned media obtained during the nodule formation and premineralization phases of bone matrix formation. These results suggest that products secreted by osteoblast during bone remodeling can serve as potent chemoattractant molecules for circulating breast and melanoma tumors.
An early study conducted by Mundy et al identi®ed collagen I as a chemoattractant for Walker rat tumor (clone 4), HeLa cells and human breast cancer cells (MB-MDA-231). 13 A similar effect was observed by synthetic di-and tri-peptides that contained amino acid predominately present in collagen helix. Also, the collegenase treatment of bone liberated chemotactic molecules for tumor cells. 14 Another study demonstrated that tumor cells can secret enzymes to liberate collagen I from bone. 15 Bone metastasizing PC-3 ML cells were injected into the bone medullary cavity of SCID mice femurs both in vivo and following isolation in vitro. The amount of collagen I released in the bone marrow and the blood plasma was determined by ELISA and was a function of time of incubation and number of cells injected in the femurs. The extent of collagen I released correlated with MMP-2 and -9 secretion in the bone medullary. The amount of MMP-2 and -9 released was determined by ELISA. Because the bone matrix is mostly composed of type I collagen, which is enzymatically degraded during the process of bone resorption and tumor in®ltration, these collagen fragments could play a biological role in bonedirected metastasis in vivo. 14, 15 Human epidermal growth factor (hEGF) has been identi®ed as a chemoattractant for the human prostate tumor cell line TSU-pr1 (Table 1) . 16 Secretory proteins produced from cell lines MG-63 (osteosarcoma), SK-ES-1 (Ewing's sarcoma), and KG-1 (leukemia) promoted chemomigration of TSU-pr 1 prostate tumor cells in a dosedependent manner in Boyden chambers. Various cytokines normally present in bone and lymph nodes were evaluated as possible chemotactic agents for TSU-pr 1, which included interleukin-1 alpha, interleukin-2, interleukin-6, tumor necrosis factor-beta, transforming growth factor-beta, interferon alpha 2-a, EGF and granulocytemacrophage colony-stimulating factor. Only EGF was shown to stimulate chemomigration of the prostate tumor cell line through the Boyden chamber in a dose- Figure 1 Proposed model for chemotaxis and cell adhesion in prostate cancer metastasis to the bone. Prostate cancer cells (CaP) in the bone marrow microvessel are attracted to the bone matrix by chemotactic factors (ie osteonectin, TGF-b, IGF-I and II, EGF). 16, 17 The prostate cancer cell initially interacts with a selectin molecule (ie galectin-3), and then an intregin like molecule (ie LFA-1) on the apical side of the human bone marrow endothelial (HBME) cells. 26 This interaction of the cancer cell with endothelium results in extravasation of the cancer cell from the circulation. 24 The abundance of TGF-b in the bone microenvironment stimulates the prostate cancer cell to express a2b1 (collagen I receptor) as they interact with osteablast cells. 3, 37 Finally, the prostate cancer cell adheres to the bone matrix which is in primarly composed of collagen I. The release of growth factors from the bone matrix by osteoclast activity stimulates cell division and ultimately tumor growth in the bone. 3 Cell adhesion and chemotaxis CR Cooper and KJ Pienta dependent manner. This chemomigration was inhibited by treatments with monoclonal antibody to hEGF receptor and staurosporine (a compound that prevents EGF receptor phosphorylation and subsequent function). 17 Furthermore, EGF-immunoreactive proteins were identi®ed in secretory proteins isolated from conditioned medium of previously mentioned cell lines by Western blot analysis. Data generated from these two studies strongly suggest that EGF present in the lymph node and medullary bone may act as a chemoattractant for prostate tumor cell preferential colonization.
Festuccia et al identi®ed transforming growth factor (TGF)-beta-1 as a chemoattractant for bone metastasizing PC-3 cells (Table 1) . 18 Osteoblast conditioned media enhanced the chemomigration and invasion of reconstituted basement membrane. The increased chemotaxis and invasion was blocked by neutralizing TGF-b 1 polyclonal antibody but not by elution of osteoblast conditioned media in agarose ± heparin columns. This demonstrates that TGF-b 1 is responsible for this activity and not EGFlike proteins. The difference between this study and Rajan et al's could be explained by the use of different types of prostate cancer cell lines. 16, 18 Together, these two investigations demonstrate the heterogeneity of prostate cancer cell lines because TGF-b 1 was a chemoattractant for and EGF was a chemoattractant for TSU-pr 1. Another study demonstrated that bone-derived insulin-like growth factor I and II increased chemotaxis of PC-3, LNCaP (derived from prostatic lymph node metastasis), and DU-145 (derived from prostatic brain metastasis). 19 The chemotactic activity of IGF I and II was not evaluated in studies mentioned earlier. 16, 18 Therefore, it is possible that IGF I and II have a chemotactic effect on TSU-pr1 cells as well.
A recent investigation demonstrated that osteonectin is a bone-derived chemoattractant for bone metastasizing prostate cancer cells (Table 1) . 20 Osteonectin does not stimulate the growth of prostate and breast cancer cells in vitro or in vivo. In addition, this low glycosylated calcium and collagen-binding protein enhances matrix metalloprotease activity in prostate and breast cancer cells exclusively. This suggests that prostate cancer cell metastasis to the bone is, in part, regulated by osteonectin ability to facilitate chemotaxis, protease activity and invasion.
Cell adhesion
Adhesive interactions between similar cell type (homophilic), different cell types (heterophilic), and cells and the extracellular matrix are important steps in mediate organspeci®c metastasis. 21 ± 23 Pauli and Lee demonstrated that the endothelial cell lining the microvessel of organs are in part responsible for site-speci®c metastasis. 22 In their study, bovine aortic endothelial cells (BAEC) were modulated by extracts derived for speci®c organ extracellular matrices called tumor attachment modulators (TAMs). Because endothelial cells derived from different organs vary signi®cantly in the expression of surface protein, TAMs from speci®c organs would encourage BAEC to expression surface proteins typical of the microvascular endothelium in a given organ that may account for sitespeci®c tumor cell adhesion. The data for this investigation showed that both lung-and liver-metastasizing tumor cells' adhesion to BAEC is signi®cantly increased after growth on dishes coated with lung and liver TAMs, respectively. The underlying subendothelial extracellular matrices also mediate site-speci®c metastasis. 23 Studies have suggested that ®bronectin, which is a predominate molecule in subendothelial extracellular matrix, contributed to the preferential binding of metastatic cells to the extracellular matrix of endothelial cells vs the apical surface of the endothelium by altering the apical TAMs. 24, 25 The interaction of tumor cells to the microvascular endothelium is described in the docking and locking hypothesis (Figure 1) . 26 
The host ± tumor interactions involved in prostate cancer metastasis to skeletal bones were examined at the endothelial cell level similar to studies above. A bone metastasizing phenotype of Dunning R3327 subline MAT-LyLu (MLL) was developed by inoculation of these cells into the left ventricle of the heart, which result in spinal metastases in all animals. 27 The bone colonizing phenotype was enhanced by sequential inoculation of bone marrow-derived carcinoma cells into the left ventricle, resulting in the selection of MLL-B5. Data generated from adhesion assays demonstrated that MLL-B5 adhered more to rat bone marrow derived endothelial cells (BMEC) compared to ®broblasts, nonenriched BMderived stromal cells, osteoblasts, and rat liver sinusoidal endothelial cells. In addition, the adhesion of MLL-B5 to BMEC was signi®cantly greater than adhesion of the parental MLL subline.
In our laboratory, human bone marrow endothelial cells (HBME-1) were isolated and transformed by SV40 large T antigen. 28 The ability of prostatic cancer cell lines and others to adhere to HBME-1 and human umbilical vein endothelial cells (HUVEC) were evaluated by adhesion assays. All cell lines tested adhered preferentially to HBME compared to HUVEC (Figure 2) . The prostate cancer cell lines adhered to the bone marrow derived endothelial cell line better than endothelial cell lines from other sites. Using antibodies, Lehr and Pienta were able to reduce PC-3 cell adhesion with galactose rich modi®ed citrus pectin and the following antibodies: galectin-3, vascular cell adhesion molecule (VCAM), CD11a (alpha-L), CD18 (beta-2), and leukocyte functional antigen-1 (LFA-1) (Figure 3) . 28 Another study showed that galectin-3 is expressed on the surface of a variety of rodent microvessel endothelium, and a subsequent study in our lab showed that PC-3 cells expressed galectin-3 (Pacis et al, manuscript submitted). 29 This data suggests that the galectin-3, VCAM, alpha-L, beta 2, and LFA-1 all may play partial role in tumor cell adhesion to HBME-1.
The role integrins play in tumor cell adhesion is well documented. 30 A recent study demonstrated that alpha-3, alpha-5, beta-1 and alpha-(v) beta-3 integrins are involved in prostate cancer cell adhesion to HUVEC. 31 Lehr and Pienta demonstrated that a high concentration (0.5 mM) of peptides containing arginine ± glycine ± aspartic (RGD) sequences blocked adhesion by 70%, suggesting integrins are important for tumor cell interaction with HBME-1. 28 Another investigation demonstrated that nude mice injected intravenously with Chinese hamster ovary cells transfected with alpha-4 beta-1 produced bone metastasis. 32 Bone metastasis was inhibited by antibody to alpha-4 or VCAM-1, a ligand for alpha-4 beta-1 integrins. Putz et al showed that cell lines derived from disseminated prostate, breast, lung and colon tumor cells in bone marrow expressed beta-1, beta-3, and alpha-v integrin subunits. 33 With the exception of LC-MI, a bone metastasizing lung tumor cell line, all cell lines expressed alpha-5 ( Table 2 ). In addition to the integrins shared with these bone metastasis cell lines, they all expressed MUC18/ melanoma cell adhesion molecule (MCAM), intercellular adhesion molecule-1 (ICAM-1), LFA-3 and CD44s.
Several early studies have evaluated the surface expression of integrins on the commonly available prostatic cancer cell lines. 34 ± 36 Witkowski et al, analyzed the alpha and beta subunits on DU145 (a cell line derived from a brain metastasis of the prostate). PC-3 (a cell line derived for a bone metastasis of the prostate), 431P (a highly metastatic variant of PC-3 derived from it serial passage in nude mice), and LNCaP (a cell line derived from a lymph node metastasis of the prostate). 35 The results suggest that bone metastasizing prostatic cancer cell has more beta 3 and fewer beta 1 subunits compared Figure 2 Preferential adhesion of prostate cancer cell to human bone marrow endothelial cell (HBME-1) (black bar) relative to human umbilical vein endothelial cells (HUVECs) (gray bar). LNCaP was derived from a lymph node metastasis. TSU and DU-145 was derived from brain and dura metastases, respectively. PC-3 and PC-3 M were derived from a bone metastasis. Spinal met is a cell line that was developed in our laboratory and derived from a patient with hormone-refractory prostate cancer. Adapted from Lehr and Pienta. 
with cell lines that were not derived from bone metastasis. Alpha 4 was not expressed in any prostatic cancer cell lines. Rokhlin and Cohen did a similar study using the same cell lines except 431P. 35 Instead, they used a primary prostate tumor cell line. Regarding alpha-2, 3, 5, beta-1, and ICAM-1, there were no differences in their expression on PC-3 cells compared to other prostate cancer cell lines. However, alpha 5 beta-1 was less expressed on DU145 and PC-3, more expressed in normal epithileal cell, ND, and absent in LNCaP. Haywood-Reid et al demonstrated the bone metastasizing PC-3 had a greater expression of alphas-1, 3 and 6 and beta-1 subunits compared with prostate tumors that were not derived from bone metastasis. 36 This suggests that these subunits may play a role in prostate cancer localization to the bone. All three of the above investigations had different outcomes regarding the expression of beta-1 in PC-3 cells relative to other cell lines. Furthermore, there were discrepancies between Haywood-Reid et al and Witkowski et al regarding beta-3. 34, 36 Therefore, the roles of beta-1 and -3 in prostate cancer metastasis to the bone cannot be determined from this information. Notably, alpha-4 beta-1 was not expressed in any cell lined tested in this investigation. A recent investigation demonstrated that the integrin expression in prostate cancer cells could be upregulated by a bone-derived cytokine. 18 Conditioned media produced by osteoblasts was shown to contain TGF-beta. In addition to promoting PC-3 chemotaxis, it increased PC-3 cell adhesion and spreading on matrigel, laminin, collagen IV and collagen I. Immuno¯uorescence analysis demonstrated that alpha-2 beta-1 and alpha-3 beta-1 integrins were upregulated in TGF-beta treated cells. A competition study, further established that PC-3 adhesion to collagen I and matrigel was reduced with anti-alpha-2 and -3 and anti-beta-1 treatments. These results provided evidence that TGF-beta present in the bone can in¯uence prostate cancer adhesion and invasion to bone matrix by modulating surface expression of selected integrins. Other earlier studies noted the TGF-beta mediated expression of alpha-2 beta-1 on prostate cancer cells and their resulting enhanced adhesion to bone matrix (Table 3) . 37, 38 Therefore, in vitro conditions clearly alter integrin expression and could account for the discrepant results found in some of these studies.
Animal models
Although the phenomena of cancer metastasis to the skeleton has been dif®cult to demonstrate in rodent animal models, it has been accomplished and reported. 39 ± 42 Most models were developed by intracardiac injection of tumor cells into the left ventricle and tail vein injection of tumor cells during temporal inferior vena cava occlusion. Using these methods a variety of tumor cell types such as lung, prostate, breast, and melanoma reproducibly home to bone. 27,39,43 ± 45 For a general review of prostate cancer models, the readers are encouraged to see Royai et al. 46 The LNCaP model was developed by coinjection of LNCaP and human osteosarcoma cell line MS into castrated and intact athymic male mice (Table 4) . 7 This procedure ultimately resulted in the development of the C4-2B cell line, which metastasizes to bone in mice. This cell line was derived from a castrated host and is therefore androgen-independent. Cytogenetic analysis demonstrated that this subline shared common marker chromosomes with the parental cell line LNCaP.
Gingrich et al demonstrated metastasis in the transgenic adenocarcinoma mouse prostate (TRAMP) model. 47 The probasin-SV40 T antigen transgene was expressed in mice at 8 weeks of age. Metastasis was evident as early as 12 weeks of age. Bone metastasis occasionally occurred at 22 ± 23 weeks of age. This model provides tumors to characterize the early molecular events necessary for prostate cancer development, progression and metastasis.
Recently, a model for prostate cancer metastasis to bone was developed by implantation of green¯uorescent protein (GFP) expressing human prostate cancer cells in the prostate of nude mice. 41 PC-3 expressing GFP were later detected in skull, rib, pelvis, femur and the tibia of the host. In addition to skeletal metastases, the brain, spinal cord, lung, plural membrane, liver, kidney and adrenal gland were involved. The metastatic pattern of prostate cancer in this model mirrored observations in Cell adhesion and chemotaxis CR Cooper and KJ Pienta human disease. 41 One limitation to most models is they do not allow for the scienti®c investigation of human tumor cells' interaction with various human the organ microenvironments. 42 The notion of species-speci®c interaction of tumor cell with organ microenvironment was further substantiated by Nemeth et al. 42 In this study, the SCID-human (hu) model was modi®ed to evaluate the ability of circulating human prostate cancer cells to home to macroscopic fragments from human bone and other organs. Tumor cells were injected intravenously or transdermally (ie directly into the implanted tissue fragments). Circulating PC-3 cells successfully colonized human bone fragment in approximately 26% of mice injected. Human lung or intestine implants, mouse skeleton, or other mouse organs were not colonized by PC-3, thus implicating both species and tissue-speci®c factors involved in bone metastasis. In this model, the species and tissue speci®c mechanisms required for prostate cancer cell interaction with bone components can be more properly evaluated.
Conclusion
It appears that the homing of prostate cancer cell to bone may be the result of speci®c chemoattractants and adhesion molecules, some which have been identi®ed, others which have not been identi®ed ( Figure 1 ). Collagen I, a major component of the bone matrix, is chemotactic for breast, HeLa and Walker rat tumor cells. 13 TGF-B and EGF are chemotactic for prostate cancer cells. 16, 18 Several cell adhesion molecules have been identi®ed as playing a role in bone metastasis of a variety of tumors. Galectin-3, VCAM-1, CD11a, CD18, integrins and LFA-1 have been implicated in prostate cancer adhesion to bone derived endothelial cells. 28 Alpha-2 beta-1 and alpha-3 beta-1 were responsible for prostate cancer cell adhesion to collagen I, and these integrins' expression was upregulated in prostate cancer cells with TGF-beta treatment (Table 3) . 37, 38 To study the mechanisms involved in bone metastases, several animal models are under development. Most models were developed by injection of tumor cells into the left ventricle or tail vein during temporary inferior vena cava occlusion. 38, 44 However, models developed by these two methods do not permit investigations of human tumor cell interactions with human organ microenvironments. A modi®ed SCID-hu model established by Nemeth et al, allowed for such investigation by implanting human bone in SCID mice. 40 Prostate tumor cells in circulation would home to exclusively to human bone.
Bone metastases are of great clinical importance because they signi®cantly reduce the quality of life of cancer patients. The cellular mechanisms responsible for this phenomena warrant further elucidation in order to construct an effective therapeutic regimen.
